Development stage biopharmaceutical company AzurRx BioPharma, Inc. (NASDAQ: AZRX) yesterday announced that it has received proceeds of approximately $2.04 million from the exercise of a total of 851,987 outstanding common stock purchase warrants. Per the update, the exercise transactions were negotiated with warrant holders as a means of raising additional working capital and were completed under the terms of warrant repricing agreements, copies of which were filed with the Securities and Exchange Commission on January 5, 2018. “We appreciate the support our warrant holders have shown the Company,” Thijs Spoor, president and CEO of AzurRx, stated in the news release. “We believe 2018 will be an instrumental year for AzurRx, as we continue to build value with our MS1819 and AZX1101 programs.”
To view the full press release, visit http://nnw.fm/sQE3g
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information on the company can be found at www.AzurRx.com
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
